A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 mg Fixed Dose Combination tablets compared with the individual components linagliptin 5 mg, BI 10773 25 mg, and BI 10773 10 mg) for 52 weeks in treatment naïve and metformin treated patients with type 2 diabetes mellitus with insufficient glycaemic control

BOEHRINGER ING.0 个研究点目标入组 2,746 人开始时间: 2011年11月29日最近更新: 2013年9月30日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 2,746

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Diagnosis of type 2 diabetes mellitus prior to informed consent 2. Male and female patients on diet and exercise regimen who are drug-naive (defined as absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomization) or pre-treated with metformin (>=1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label)unchanged for 12 weeks prior to randomisation. 3. HbA1c >= 7.0% and <= 10.5% (>= 53.0 mmol/mol and <= 91.3 mmol/mol) at Visit 1 (screening) 4. Age >= 18 years 5. Body Mass Index (BMI) <=45 kg/m2 at Visit 1 (screening) 6. Signed and dated written informed consent by date of Visit 1 in accordance with GCP and local legislation
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2060
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 686

排除标准

•1. Uncontrolled hyperglycemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day). 2. Any other antidiabetic drug within 12 weeks prior to randomization (except metformin background therapy as defined via inclusion criterion 2) Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent 4. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening and/or run-in period 5. Impaired renal function, defined as eGFR <60 ml/min (MDRD formula) as determined during screening and/or run-in period 6. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption 7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years 8. Blood dyscrasias or any disorders causing hemolysis or unstable (shortened half-life) red blood cell (e.g. malaria, babesiosis, hemolytic anemia) 9. Contraindications to metformin according to the local label 10. Treatment with anti-obesity drugs within 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight 11. Current treatment with systemic steroids (other than inhalative steriods) at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM 12. Pre-menopausal women (last menstruation <=1 year prior to informed consent) who: - are nursing or pregnant or - are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the trial and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, complete sexual abstinence (if acceptable by local health authorities), double barrier method and vasectomized partner 13. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to trial procedures or trial drug intake, in the judgment of the investigator 14. Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial or participation in the follow-up period of another trial (partipation in observational studies is permitted) 15. Any other clinical condition that, in the opinion of the investigator, would jeopardize patient's safety while participating in this clinical trial

研究者

发起方

BOEHRINGER ING.

相似试验

进行中（未招募）

不适用

Efficacy and safety of BI 10773/BI 1356 Fixed Dose Combination iin treatment naïve and metformin treated type 2 diabetes patientsMedDRA version: 16.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes Mellitus

EUCTR2011-000383-10-BGBoehringer Ingelheim RCV GmBH & Co KG1,300

进行中（未招募）

不适用

EUCTR2011-000383-10-HUBoehringer Ingelheim RCV GmBH & Co KG1,300

进行中（未招募）

不适用

Efficacy and safety of BI 10773/BI 1356 Fixed Dose Combination iin treatment naïve and metformin treated type 2 diabetes patientsMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes Mellitus

EUCTR2011-000383-10-EEBoehringer Ingelheim RCV GmBH & Co KG1,300

进行中（未招募）

1 期

Efficacy and safety of BI 10773/BI 1356 Fixed Dose Combination iin treatment naïve and metformin treated type 2 diabetes patientsMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes Mellitus

EUCTR2011-000383-10-ESBoehringer Ingelheim España, S.A.2,505

进行中（未招募）

不适用

Efficacy and safety of BI 10773/BI 1356 Fixed Dose Combination iin treatment naïve and metformin treated type 2 diabetes patientsType 2 Diabetes Mellitus

EUCTR2011-000383-10-DKBoehringer Ingelheim Danmark A/S1,300